Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 3/2015

01-03-2015 | Original Article

Preclinical evaluation of [18F]2FNQ1P as the first fluorinated serotonin 5-HT6 radioligand for PET imaging

Authors: Guillaume Becker, Julie Colomb, Véronique Sgambato-Faure, Léon Tremblay, Thierry Billard, Luc Zimmer

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 3/2015

Login to get access

Abstract

Purpose

Brain serotonin 6 receptor (5-HT6) is one of the most recently identified serotonin receptors. It is a potent therapeutic target for psychiatric and neurological diseases, e.g. schizophrenia and Alzheimer’s disease. Since no specific fluorinated radioligand has yet been successfully used to study this receptor by positron emission tomography (PET) neuroimaging, the objective of the present study was to study the first 5-HT6 18F-labelled radiotracer.

Methods

2FNQ1P, inspired by the quinolone core of a previous radiotracer candidate, GSK215083, was selected according its 5-HT6 affinity and selectivity and was radiolabelled by 18F nucleophilic substitution. The cerebral distribution of [18F]2FNQ1P was studied in vivo in rats, cats and macaque monkeys.

Results

The chemical and radiochemical purities of [18F]2FNQ1P were >98 %. In rats, in vitro competition with the 5-HT6 antagonist, SB258585, revealed that the radioligand was displaced dose dependently. Rat microPET studies showed low brain uptake of [18F]2FNQ1P, reversed by the P-glycoprotein inhibitor, cyclosporin. On the contrary, PET scans in cats showed good brain penetration and specific striatal binding blocked after pretreatment with unlabelled 2FNQ1P. PET scans in macaque monkeys confirmed high specific binding in both cortical and subcortical regions, specifically decreased by pretreatment with the 5-HT6 receptor antagonist, SB258585.

Conclusion

2FNQ1P was initially selected because of its suitable characteristics for 5-HT6 receptor probing in vitro in terms of affinity and specificity. Although in vivo imaging in rats cannot be considered as predictive of the clinical characteristics of the radiotracer, [18F]2FNQ1P appeared to be a suitable 5-HT6 PET tracer in feline and primate models. These preclinical results encourage us to pursue the clinical development of this first fluorinated 5-HT6 PET radiotracer.
Literature
1.
Woolley ML, Marsden CA, Fone KC. 5-ht6 receptors. Curr Drug Targets CNS Neurol Disord 2004;3:59–79.CrossRefPubMed
2.
Monsma Jr FJ, Shen Y, Ward RP, Hamblin MW, Sibley DR. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol 1993;43:320–7.PubMed
3.
Ruat M, Traiffort E, Arrang JM, Tardivel-Lacombe J, Diaz J, Leurs R, et al. A novel rat serotonin (5-HT6) receptor: molecular cloning, localization and stimulation of cAMP accumulation. Biochem Biophys Res Commun 1993;193:268–76.CrossRefPubMed
4.
Kohen R, Metcalf MA, Khan N, Druck T, Huebner K, Lachowicz JE, et al. Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor. J Neurochem 1996;66:47–56.CrossRefPubMed
5.
Glennon RA. Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7). J Med Chem 2003;46:2795–812.CrossRefPubMed
6.
Boess FG, Riemer C, Bös M, Bentley J, Bourson A, Sleight AJ. The 5-hydroxytryptamine6 receptor-selective radioligand [3H]Ro 63–0563 labels 5-hydroxytryptamine receptor binding sites in rat and porcine striatum. Mol Pharmacol 1998;54:577–83.PubMed
7.
East SZ, Burnet PW, Leslie RA, Roberts JC, Harrison PJ. 5-HT6 receptor binding sites in schizophrenia and following antipsychotic drug administration: autoradiographic studies with [125I]SB-258585. Synapse 2002;45:191–9.CrossRefPubMed
8.
Hirst WD, Minton JA, Bromidge SM, Moss SF, Latter AJ, Riley G, et al. Characterization of [(125)I]-SB-258585 binding to human recombinant and native 5-HT(6) receptors in rat, pig and human brain tissue. Br J Pharmacol 2000;130:1597–605.CrossRefPubMedCentralPubMed
9.
Roberts JC, Reavill C, East SZ, Harrison PJ, Patel S, Routledge C, et al. The distribution of 5-HT(6) receptors in rat brain: an autoradiographic binding study using the radiolabelled 5-HT(6) receptor antagonist [(125)I]SB-258585. Brain Res 2002;934:49–57.CrossRefPubMed
10.
Dawson LA. The central role of 5-HT6 receptors in modulating brain neurochemistry. Int Rev Neurobiol 2011;96:1–26.CrossRefPubMed
11.
Arnt J, Olsen CK. 5-HT6 receptor ligands and their antipsychotic potential. Int Rev Neurobiol 2011;96:141–61.CrossRefPubMed
12.
13.
Quiedeville A, Boulouard M, Da Silva Costa-Aze V, Dauphin F, Bouet V, Freret T. 5-HT6 receptor antagonists as treatment for age-related cognitive decline. Rev Neurosci 2014;25:417–27.CrossRefPubMed
14.
Heal D, Gosden J, Smith S. The 5-HT6 receptor as a target for developing novel antiobesity drugs. Int Rev Neurobiol 2011;96:73–109.CrossRefPubMed
15.
Lancelot S, Zimmer L. Small-animal positron emission tomography as a tool for neuropharmacology. Trends Pharmacol Sci 2010;31:411–7.CrossRefPubMed
16.
Zimmer L, Luxen A. PET radiotracers for molecular imaging in the brain: past, present and future. Neuroimage 2012;61:363–70.CrossRefPubMed
17.
Lee CM, Farde L. Using positron emission tomography to facilitate CNS drug development. Trends Pharmacol Sci 2006;27:310–6.CrossRefPubMed
18.
Branchek TA, Blackburn TP. 5-ht6 receptors as emerging targets for drug discovery. Annu Rev Pharmacol Toxicol 2000;40:319–34.CrossRefPubMed
19.
Tang S, Verdurand M, Joseph B, Lemoine L, Daoust A, Billard T, et al. Synthesis and biological evaluation in rat and cat of [18F]12ST05 as a potential 5-HT6 PET radioligand. Nucl Med Biol 2007;34:995–1002.CrossRefPubMed
20.
Ahmed M, Jones MC, MacDonald GJ, Moss SF, Thompson M, Wade CE, Witty D. Preparation of arylsulfonyl(diazacycloalkyl)quinolines for treatment of CNS disorders. Patent Application Publication WO2003080580A2 2003.
21.
Martarello L, Ahmed M, Chuang AT, Cunnigham VJ, Jakobsen S, Johnson CN, et al. Radiolabelling and in vivo evaluation of [11C]GSK210583 as a potential 5-HT6 PET radioligand in the porcine brain. J Labelled Comp Radiopharm 2005;48:341.
22.
Comley RA, Salinas C, Mizrahi R, Vitcu I, Ng A, Hallett W, et al. Biodistribution and radiation dosimetry of the serotonin 5-HT(6) ligand [11C]GSK215083 determined from human whole-body PET. Mol Imaging Biol 2012;14:517–21.CrossRefPubMed
23.
Parker CA, Gunn RN, Rabiner EA, Slifstein M, Comley R, Salinas C, et al. Radiosynthesis and characterization of 11C-GSK215083 as a PET radioligand for the 5-HT6 receptor. J Nucl Med 2012;53:295–303.CrossRefPubMed
24.
Pazos A, Probst A, Palacios JM. Serotonin receptors in the human brain--IV. Autoradiographic mapping of serotonin-2 receptors. Neuroscience 1987;21:123–39.CrossRefPubMed
25.
Liu F, Majo VJ, Prabhakaran J, Milak MS, John Mann J, Parsey RV, et al. Synthesis and in vivo evaluation of [O-methyl-11C] N-[3,5-dichloro-2-(methoxy)phenyl]-4-(methoxy)-3-(1-piperazinyl)benzenesulfonamide as an imaging probe for 5-HT6 receptors. Bioorg Med Chem 2011;19:5255–9.CrossRefPubMed
26.
Zhang LV A, Anderson D, Beck E, Blumberg L, Bocan T, Bronk B, et al. Development of design and selection parameters to accelerate the discovery process of novel CNS PET ligands and their application in the identification of a potential 5HT6 PET ligand [11C]PF-1. J Labelled Comp Radiopharm 2011;54:S292.CrossRef
27.
Black LA. Radiolabeled 5-HT6 ligands. Patent Application Publication US 2013/0343993A1.
28.
Colomb J, Becker G, Fieux S, Zimmer L, Billard T. Syntheses, radiolabelings, and in vitro evaluations of fluorinated PET radioligands of 5-HT6 serotoninergic receptors. J Med Chem 2014;57:3884–90.CrossRefPubMed
29.
Snyder WT. A stereotaxic atlas of the cat brain. Chicago: University of Chicago Press; 1961.
30.
Ballanger B, Tremblay L, Sgambato-Faure V, Beaudoin-Gobert M, Lavenne F, Le Bars D, et al. A multi-atlas based method for automated anatomical Macaca fascicularis brain MRI segmentation and PET kinetic extraction. Neuroimage 2013;77:26–43.CrossRefPubMed
31.
Gérard C, Martres MP, Lefèvre K, Miquel MC, Vergé D, Lanfumey L, et al. Immuno-localization of serotonin 5-HT6 receptor-like material in the rat central nervous system. Brain Res 1997;746:207–19.CrossRefPubMed
32.
Mitchell ES, Neumaier JF. 5-HT6 receptors: a novel target for cognitive enhancement. Pharmacol Ther 2005;108:320–33.CrossRefPubMed
33.
Fagerholm U. The highly permeable blood-brain barrier: an evaluation of current opinions about brain uptake capacity. Drug Discov Today 2007;12:1076–82.CrossRefPubMed
34.
Waterhouse RN. Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. Mol Imaging Biol 2003;5:376–89.CrossRefPubMed
35.
Elsinga PH, Hendrikse NH, Bart J, Vaalburg W, van Waarde A. PET studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNS. Curr Pharm Des 2004;10:1493–503.CrossRefPubMed
36.
Laćan G, Plenevaux A, Rubins DJ, Way BM, Defraiteur C, Lemaire C, et al. Cyclosporine, a P-glycoprotein modulator, increases [18F]MPPF uptake in rat brain and peripheral tissues: microPET and ex vivo studies. Eur J Nucl Med Mol Imaging 2008;35:2256–66.CrossRefPubMed
37.
Hirst WD, Abrahamsen B, Blaney FE, Calver AR, Aloj L, Price GW, et al. Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling. Mol Pharmacol 2003;64:1295–308.CrossRefPubMed
38.
Borsini F, Bordi F, Riccioni T. 5-HT6 pharmacology inconsistencies. Pharmacol Biochem Behav 2011;98:169–72.CrossRefPubMed
Metadata
Title
Preclinical evaluation of [18F]2FNQ1P as the first fluorinated serotonin 5-HT6 radioligand for PET imaging
Authors
Guillaume Becker
Julie Colomb
Véronique Sgambato-Faure
Léon Tremblay
Thierry Billard
Luc Zimmer
Publication date
01-03-2015
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 3/2015
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-014-2936-y

Other articles of this Issue 3/2015

European Journal of Nuclear Medicine and Molecular Imaging 3/2015 Go to the issue

Original Article

Nonsurgical giant cell tumour of the tendon sheath or of the diffuse type: Are MRI or 18F-FDG PET/CT able to provide an accurate prediction of long-term outcome?

Original Article

Test–retest reliability of the novel 5-HT1B receptor PET radioligand [11C]P943

Book Review

S. Ted Treves: Pediatric nuclear medicine and molecular imaging

Original Article

Zone-size nonuniformity of 18F-FDG PET regional textural features predicts survival in patients with oropharyngeal cancer

Original Article

Prognostic impact of 18F-FDG PET/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer

Image of the Month

68Ga-NOTA-exendin-4 PET/CT in detection of occult insulinoma and evaluation of physiological uptake